News
"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...
Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...
Novavax (NasdaqGS:NVAX) recently reported a significant financial turnaround for Q1 2025, demonstrating substantial revenue growth and net income improvements. The amending of its collaboration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results